Salarius Pharmaceuticals

Decoy Therapeutics, operating under the former shell of Salarius Pharmaceuticals, has executed a strategic pivot from oncology to infectious disease, now focused on engineering broad-spectrum antiviral therapeutics. Its core mission is to overcome the limitations of narrow, single-pathogen treatments by developing Designable Multi-Antivirals (DMAVs) that target conserved viral entry mechanisms across entire viral families. The company's strategy is underpinned by the IMP³ACT platform, which uses AI-driven design and rapid synthesis to create peptide conjugates, with lead programs in preclinical development for pan-coronavirus and tripledemic indications. Key achievements include strategic partnerships for AI/cloud infrastructure and a commitment to developing a globally accessible manufacturing platform.

The IMP³ACT platform is an integrated, AI-enabled system for the design, rapid synthesis, and scalable manufacturing of peptide conjugate therapeutics, focusing on creating broad-spectrum antivirals that target conserved viral mechanisms.

Decoy competes in the emerging field of broad-spectrum antivirals against large pharma and biotechs developing next-generation oral drugs and monoclonal antibodies. Its key differentiators are the combination of AI-driven design for conserved targets, a peptide conjugate modality aimed at durability, and a focus on convenient nasal spray delivery for both prophylaxis and treatment.